


REMARKS

**BEST AVAILABLE COPY**

Applicants amend the specification for purposes of adding the priority information and amending the Title. The attached Abstract has been placed on a separate sheet of paper according to US practice and amended per the Examiner's request. Applicants believe that no fees are due in connection with the filing of this paper other than those specifically authorized herewith. However, should any other fees be deemed necessary to effect the timely filing of this paper the Commissioner is hereby authorized to charge such fees to Deposit Account No. 07-1392.

Respectfully submitted,

  
John L. Lemanowicz  
Attorney for Applicants  
Registration No. 37,380

Date: 23 February, 2006  
Glaxo SmithKline  
Five Moore Drive, PO Box 13398  
Research Triangle Park  
North Carolina 27709  
(919) 483-8247